tirzepatide snoring Sleep apnea: Zepbound, Mounjaro improves symptoms in clinical trial Tirzepatide shows dual benefits in

You can read the abstract of this article at LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept A novel dual GIP and GLP-1 receptor agonist, LY3298176, was developed to determine whether the metabolic action of GIP adds to the established clinical benefits of selective GLP-1 receptor agonists in type 2 diabetes mellitus (T2DM)

Source data Source Data (download ZIP Statistical source data for all figures

I think it helps to view the timeline like compound interest

It is important to note that 2.5 mg is considered a loading or initiation dose

Paolillo S, Basile C, DellAversana S, et al